BIOMAT Database Logo BIOMAT Database Logo

[Mechanisms of action of angiotensin I converting enzyme inhibitors]. 1994

A Wiecek
Katedry i Kliniki Nefrologii, SI.A.M., Katowicach.

Different mechanisms of action of angiotensin I converting enzyme (ACE) inhibitors are now known. ACE inhibitors can decrease angiotensin II synthesis directly in the tissue. The well known are now renal and vascular renin-angiotensin systems. ACE inhibitors do influence on the blood pressure and proliferation of cardiomyocytes, endothelial and mesangial cells also through activation of the kallikrein-kinin system and production of prostaglandin E, prostacyclin, nitric oxide and medullipin.

UI MeSH Term Description Entries
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Wiecek
Angiotensin converting enzyme inhibitors. I. Pharmacology.
December 1988, American heart journal,
A Wiecek
Antihypertensive action of angiotensin-I converting enzyme inhibitors in the kidney.
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
A Wiecek
Angiotensin-converting enzyme inhibitors: mechanisms of action and implications in anesthesia practice.
January 2003, Current pharmaceutical design,
A Wiecek
Duration of action of angiotensin converting enzyme inhibitors.
October 1995, American journal of hypertension,
A Wiecek
Angiotensin converting enzyme inhibitors: basics (Part I).
January 1995, Le Journal medical libanais. The Lebanese medical journal,
A Wiecek
Cellular protective action of angiotensin converting enzyme inhibitors.
January 1997, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
A Wiecek
Peptide inhibitors of pulmonary angiotensin I converting enzyme.
September 1971, Biochimica et biophysica acta,
A Wiecek
Inhibitors of the pulmonary angiotensin I-converting enzyme.
December 1972, Biochimica et biophysica acta,
A Wiecek
Renal effects of angiotensin-I converting enzyme inhibitors.
June 1988, The Netherlands journal of medicine,
A Wiecek
Mechanism for hypotensive action of angiotensin converting enzyme inhibitors.
January 1984, Clinical and experimental hypertension. Part A, Theory and practice,
Copied contents to your clipboard!